Jonathan Chang
Stock Analyst at Leerink Partners
(4.14)
# 1,612
Out of 4,792 analysts
553
Total ratings
37.9%
Success rate
7.7%
Average return
Main Sectors:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $9 | $4.28 | +110.28% | 1 | Jul 13, 2026 | |
| MOLN Molecular Partners AG | Reiterated: Buy | n/a | $4.18 | - | 7 | Jun 2, 2026 | |
| CMPX Compass Therapeutics | Reiterated: Buy | $11 | $2.08 | +428.85% | 1 | Apr 27, 2026 | |
| REPL Replimune Group | Downgraded: Hold | $13 → $2 | $13.60 | -85.29% | 48 | Apr 13, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $67 → $147 | $205.99 | -28.64% | 40 | Apr 13, 2026 | |
| NBTX Nanobiotix | Reiterated: Buy | $24 → $37 | $37.23 | -0.62% | 17 | Apr 1, 2026 | |
| IMTX Immatics | Reiterated: Buy | $17 | $8.50 | +100.00% | 44 | Mar 6, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $31 | $23.94 | +29.49% | 1 | Feb 3, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $20 | $11.72 | +70.65% | 51 | Jan 13, 2026 | |
| NVCR NovoCure | Reiterated: Buy | $33 → $24 | $15.50 | +54.84% | 19 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $74 | $24.24 | +205.28% | 51 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $39 | $32.45 | +20.18% | 45 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $8 → $6 | $1.59 | +277.36% | 36 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $5 | $4.08 | n/a | 38 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $0.11 → $0.09 | $0.0265 | n/a | 38 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $3.91 | n/a | 30 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $33.58 | n/a | 13 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $24.75 | n/a | 32 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.015 | n/a | 23 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1,001.22 | n/a | 1 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $50.92 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $18 → $2 | $0.0004 | n/a | 15 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.74 | n/a | 1 | Jun 1, 2022 |
Whitehawk Therapeutics
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $4.28
Upside: +110.28%
Molecular Partners AG
Jun 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.18
Upside: -
Compass Therapeutics
Apr 27, 2026
Reiterated: Buy
Price Target: $11
Current: $2.08
Upside: +428.85%
Replimune Group
Apr 13, 2026
Downgraded: Hold
Price Target: $13 → $2
Current: $13.60
Upside: -85.29%
Revolution Medicines
Apr 13, 2026
Reiterated: Buy
Price Target: $67 → $147
Current: $205.99
Upside: -28.64%
Nanobiotix
Apr 1, 2026
Reiterated: Buy
Price Target: $24 → $37
Current: $37.23
Upside: -0.62%
Immatics
Mar 6, 2026
Reiterated: Buy
Price Target: $17
Current: $8.50
Upside: +100.00%
Aktis Oncology
Feb 3, 2026
Initiated Coverage: Buy
Price Target: $31
Current: $23.94
Upside: +29.49%
Kura Oncology
Jan 13, 2026
Reiterated: Buy
Price Target: $20
Current: $11.72
Upside: +70.65%
NovoCure
Jan 13, 2026
Reiterated: Buy
Price Target: $33 → $24
Current: $15.50
Upside: +54.84%
Oct 21, 2025
Reiterated: Buy
Price Target: $74
Current: $24.24
Upside: +205.28%
Oct 13, 2025
Reiterated: Buy
Price Target: $34 → $39
Current: $32.45
Upside: +20.18%
Oct 10, 2025
Reiterated: Hold
Price Target: $8 → $6
Current: $1.59
Upside: +277.36%
Aug 18, 2025
Reiterated: Buy
Price Target: $8 → $5
Current: $4.08
Upside: n/a
Aug 13, 2025
Reiterated: Hold
Price Target: $0.11 → $0.09
Current: $0.0265
Upside: n/a
Aug 11, 2025
Reiterated: Buy
Price Target: $24
Current: $3.91
Upside: n/a
Aug 11, 2025
Reiterated: Buy
Price Target: $60
Current: $33.58
Upside: n/a
Aug 7, 2025
Reiterated: Buy
Price Target: $27
Current: $24.75
Upside: n/a
Nov 12, 2024
Reiterated: Buy
Price Target: $2
Current: $0.015
Upside: n/a
Jun 30, 2023
Reiterated: Buy
Price Target: n/a
Current: $1,001.22
Upside: n/a
Jan 11, 2023
Rated: Buy
Price Target: n/a
Current: $50.92
Upside: n/a
Nov 14, 2022
Downgraded: Hold
Price Target: $18 → $2
Current: $0.0004
Upside: n/a
Jun 1, 2022
Reiterated: Buy
Price Target: n/a
Current: $5.74
Upside: n/a